HeartBeam and AccurKardia partner on ECG tech

SANTA CLARA, Calif. & NEW YORK - HeartBeam, Inc. (NASDAQ: BEAT), a pioneer in cardiac care technology, has announced a strategic collaboration with AccurKardia, a provider of ECG-based diagnostics. The partnership aims to integrate AccurKardia’s FDA-cleared ECG analysis software into HeartBeam’s innovative devices to improve remote cardiac monitoring.

The collaboration is set to enhance HeartBeam’s upcoming commercial offerings by incorporating AccurKardia’s automated ECG interpretation platform with HeartBeam’s 3D ECG device, which is awaiting FDA clearance. With HeartBeam’s next earnings report scheduled for May 8, investors are closely monitoring the company’s progress toward commercialization. InvestingPro data reveals the company maintains a current ratio of 1.71, providing some cushion for near-term operations despite challenging market conditions. This integration is expected to facilitate faster diagnosis and treatment for cardiac arrhythmia conditions, allowing patients to monitor their heart health outside of medical facilities.

Robert Eno, CEO of HeartBeam, expressed optimism about the partnership’s potential to expedite the delivery of cardiac insights and improve patient outcomes. Juan C. Jimenez, CEO of AccurKardia, echoed these sentiments, highlighting the transformative impact of combining their technologies on cardiac health management.

AccurKardia is recognized for its cloud-based diagnostic tools and has recently achieved FDA Breakthrough Device Designation for its AI-powered detection models for Hyperkalemia and aortic stenosis. The company has also been acknowledged for its participation in the American Heart Association’s accelerator track within the MedTech Innovator program.

HeartBeam’s technology focuses on a cable-free synthesized 12-lead ECG that captures heart signals from three directions, designed for use in portable devices. The company holds numerous U.S. and international patents related to this technology.

The combined solution from HeartBeam and AccurKardia is currently in development and has not yet received FDA clearance. This collaboration represents a significant move towards more accessible and advanced cardiac care technology.

Investors and the medical community are advised to consider the forward-looking nature of this announcement, as actual results may differ from expectations due to various risks and uncertainties. This news article is based on a press release statement.

In other recent news, HeartBEAM Inc. reported its fourth-quarter 2024 earnings, revealing an EPS of -$0.73, which fell short of the forecasted -$0.17. Despite the earnings miss, the company remains focused on its innovative ECG technology, anticipating FDA clearance for its 12-lead synthesis software by the end of 2025. Benchmark analysts have maintained a Speculative Buy rating and an $8.00 price target for HeartBEAM, highlighting the company’s progress and upcoming commercial launch. HeartBEAM has already received FDA clearance for its at-home heart monitoring technology, a pivotal step towards further developments. The company recently completed an $11.5 million public offering to support operations, enhancing its financial position with a pro forma cash balance of $12.6 million at the end of 2024. As HeartBEAM prepares for its initial commercial launch, it is also exploring partnerships to bolster its market entry strategy. The company continues to advance its cable-free ECG device, targeting a significant share of the cardiac condition management market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.